-
Avelumab
- names:
Avelumab
- CAS号:
1537032-82-8
MDL Number: NA - MF(分子式): C6374H9898N1694O2010S44 MW(分子量): 142.0 Da (approximate including glycans)
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM004559-5mg | 5mg | 99.2% | ¥ 33750.00 | ¥ 33750.00 | 2-3天 | ¥ 0.00 | ||
| YZM004559-1mg | 1mg | 99.2% | ¥ 11050.00 | ¥ 11050.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | 阿维鲁单抗; |
| 英文别名 | BAVENCIO;anti-PD-L1;monoclonal antibody;MSB0010718C |
| CAS号 | 1537032-82-8 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C6374H9898N1694O2010S44 |
| 分子量 Molecular Weight | 142.0 Da (approximate including glycans) |
| 溶解度Solubility | |
| 性状 | Liquid |
| 储藏条件 Storage conditions | Pure form -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
Avelumab(CAS:1537032-82-8)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | Avelumab 为一个人 IgG1 抗PD-L1单克隆抗体,具有潜在的抗体依赖性细胞介导的细胞毒性作用 |
| Introduction | Avelumab is a fully human IgG1 antiD1monoclonal antibody with potential antibodyependent cellediated cytotoxicity. |
| Application1 | Avelumab is a programmed death ligand-1 (PD-L1) blocking antibody . It is a fully human anti-PD immunoglobulin G1 (IgG1) lambda monoclonal antibody with antineoplastic actions. |
| Application2 | |
| Application3 |
Avelumab 为一个人 IgG1 抗PD-L1单克隆抗体,具有潜在的抗体依赖性细胞介导的细胞毒性作用。
Avelumab is a fully human IgG1 anti-PD-L1monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
Avelumab是针对人免疫抑制配体编程的死亡配体1(PD-L1)蛋白的人免疫球蛋白G1(IgG1)单克隆抗体,具有潜在的免疫检查点抑制和抗肿瘤活性。avelumab与PD-L1结合并阻止PD-L1与其受体编程的细胞死亡蛋白1(PD-1)相互作用。这抑制了PD-1及其下游信号通路的激活。这可以通过激活针对过表达PD-L1的肿瘤细胞的细胞毒性T淋巴细胞(CTL)来恢复免疫功能。此外,avelumab诱导针对表达PD-L1的肿瘤细胞的抗体依赖性细胞毒性(ADCC)反应。 PD-1是一种在T细胞上表达的免疫球蛋白超家族的细胞表面受体,当被其配体激活时,会负调控T细胞的激活和效应子功能,并且在逃避宿主免疫的肿瘤中起重要作用。 PD-L1是一种跨膜蛋白,在多种肿瘤细胞类型中过表达,并且与不良预后相关,使用该试剂检查活跃的临床试验。
Avelumab is a whole antibody that binds the immunosuppressive programmed death-ligand 1 and inhibits the interaction between PD-1 and PD-L1. It prevents the formation of a PD-1/PD-L1 receptor/ligand complex that normally leads to inhibition of CD8+ T cells, and therefore inhibition of an immune reaction. Alevumab is an immunotherapeutic and antineoplastic agent that belongs to the group of immune checkpoint blockade cancer therapies. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity (ADCC).
Avelumab是一种完整抗体,可结合免疫抑制程序性死亡配体1并抑制PD-1和PD-L1之间的相互作用。 它防止形成PD-1 / PD-L1受体/配体复合物,该复合物通常会抑制CD8 + T细胞,从而抑制免疫反应。 Alevumab是一种免疫治疗和抗肿瘤药,属于免疫检查点阻断癌症治疗。 通过保留天然的Fc区,avelumab被认为参与了先天免疫系统,并可能诱导抗体依赖性细胞介导的细胞毒性(ADCC)。
Avelumab is a fully human IgG1 anti-PD-L1monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
Avelumab是针对人免疫抑制配体编程的死亡配体1(PD-L1)蛋白的人免疫球蛋白G1(IgG1)单克隆抗体,具有潜在的免疫检查点抑制和抗肿瘤活性。avelumab与PD-L1结合并阻止PD-L1与其受体编程的细胞死亡蛋白1(PD-1)相互作用。这抑制了PD-1及其下游信号通路的激活。这可以通过激活针对过表达PD-L1的肿瘤细胞的细胞毒性T淋巴细胞(CTL)来恢复免疫功能。此外,avelumab诱导针对表达PD-L1的肿瘤细胞的抗体依赖性细胞毒性(ADCC)反应。 PD-1是一种在T细胞上表达的免疫球蛋白超家族的细胞表面受体,当被其配体激活时,会负调控T细胞的激活和效应子功能,并且在逃避宿主免疫的肿瘤中起重要作用。 PD-L1是一种跨膜蛋白,在多种肿瘤细胞类型中过表达,并且与不良预后相关,使用该试剂检查活跃的临床试验。
Avelumab is a whole antibody that binds the immunosuppressive programmed death-ligand 1 and inhibits the interaction between PD-1 and PD-L1. It prevents the formation of a PD-1/PD-L1 receptor/ligand complex that normally leads to inhibition of CD8+ T cells, and therefore inhibition of an immune reaction. Alevumab is an immunotherapeutic and antineoplastic agent that belongs to the group of immune checkpoint blockade cancer therapies. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity (ADCC).
Avelumab是一种完整抗体,可结合免疫抑制程序性死亡配体1并抑制PD-1和PD-L1之间的相互作用。 它防止形成PD-1 / PD-L1受体/配体复合物,该复合物通常会抑制CD8 + T细胞,从而抑制免疫反应。 Alevumab是一种免疫治疗和抗肿瘤药,属于免疫检查点阻断癌症治疗。 通过保留天然的Fc区,avelumab被认为参与了先天免疫系统,并可能诱导抗体依赖性细胞介导的细胞毒性(ADCC)。
| 警示图 | |
| 危险性 | |
| 危险性警示 | Avelumab毒性包括可能发生致命的输液反应和/或免疫原性反应,例如肺炎,肝炎,结肠炎,肾上腺功能不全,甲状腺功能减退和甲亢,糖尿病和肾炎等。 其他常见的不良反应包括疲劳,肌肉骨骼疼痛,腹泻,恶心,与输液有关的反应,皮疹,食欲下降和周围水肿。 |
| 安全声明 | H313 |
| 安全防护 | |
| 备注 |
Avelumab toxicity includes the possibility of experiencing potentially fatal infusion reactions and/or immunogenic reactions like pneumonitis, hepatitis, colitis, adrenal insufficiency, hypo- and hyperthyroidism, diabetes mellitus, and nephritis, among others. Other common adverse effects include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, rash, decreased appetite, and peripheral edema.
| 【1】.Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016 Jun 7;7(23):33498-511. |
| 【2】.Grenga I, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016 May 20;5(5):e83. |
| 【3】.Vandeveer AJ, et al. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res. 2016 May;4(5):452-62. |
| 【4】Hamilton G, Rath B: Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther. 2017 Apr;17(4):515-523. doi: 10.1080/14712598.2017.1294156. |
| 【5】Merck-Pfizer Alliance: Avelumab Fact Sheet [Link] |
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2. [PubMed:23724846]
- Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J: Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26. [PubMed:26014098]
- Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marte JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL: Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31. [PubMed:28373007]
- Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1. [PubMed:27592805]
- Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL: Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol. 2017 Apr 4:JCO2016716795. doi: 10.1200/JCO.2016.71.6795. [PubMed:28375787]
- Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, Qi J, Wong G, Zhu X, Liu WJ, Gao S, Wang Z, Shi Y, Yang F, Gao GF, Yan J: An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017 Feb 6;8:14369. doi: 10.1038/ncomms14369. [PubMed:28165004
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


